SANA

Sana Biotechnology Inc

Add to Watchlist

Advanced Chart

4.090

+0.04(0.988%)1D

Line

Candle

YTD

High

4.180

Open

3.910

VWAP

3.90

Vol

5.47M

Mkt Cap

1.09B

Low

3.650

Amount

21.32M

EV/EBITDA(TTM)

Total Shares

221.50M

936.38M

EV/OCF(TTM)

P/S(TTM)

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.153

-26.99%

-0.171

-18.72%

-0.184

-26.21%

Estimates Revision

Stock Price

Go Up

+36.33%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast SANA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SANA is 8.25 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 4.090

Low

5.00

Averages

8.25

High

12.00

Current: 4.090

Low

5.00

Averages

8.25

High

12.00

Citizens JMP

Outperform

maintain

$5 -> $8

2025-10-30

Reason

Citizens JMP

Price Target

$5 -> $8

2025-10-30

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Sana Biotechnology to $8 from $5 and keeps an Outperform rating on the shares. Sana's enhanced Fusogen platform now offers improved specificity and expansion, with an IND filing anticipated in 2026, the analyst tells investors in a research note. Progress across multiple programs, including the modified pancreatic islet cell IST in T1D, the iPSC program nearing IND readiness, and SC291 data expected in 4Q25, combined with a $177.2M pro forma cash position, suggests the shares remain undervalued with potential upside from future Fusogen monetization, Citizens says.

Wedbush

NULL -> Outperform

initiated

2025-09-24

Reason

Wedbush

Price Target

2025-09-24

initiated

NULL -> Outperform

Reason

Wedbush initiated coverage of Sana Biotechnology with an Outperform rating and $5 price target.

Wedbush

Outperform

initiated

2025-09-24

Reason

Wedbush

Price Target

2025-09-24

initiated

Outperform

Reason

As previously reported, Wedbush initiated coverage of Sana Biotechnology with an Outperform rating and $5 price target. Lead candidate SC451 is an off-the-shelf pancreatic islet cell therapy for type 1 diabetes, which can address the limitations of device-based management and islet cell transplant. A second program, SG299, is an in vivo CART cell therapy candidate which may address the hurdles of cost, lymphodepletion, and access associated with current autologous CAR-T approaches. Both programs may enter the clinic as early as 2026, the firm notes. Wedbush views Sana as holding scarcity value for both its immune evasion and in vivo CART platforms, with substantial long-term growth potential.

Morgan Stanley

Maxwell Skor

Overweight

initiated

$12

2025-07-02

Reason

Morgan Stanley

Maxwell Skor

Price Target

$12

2025-07-02

initiated

Overweight

Reason

Morgan Stanley analyst Maxwell Skor assumed coverage of Sana Biotechnology with an Overweight rating and $12 price target. Six-month data for UP421 in type 1 diabetes show continued cell survival and insulin production without immunosuppression, notes the analyst, who looks forward to an investigational new drug filing for the company's proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451, as early as next year.

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$11

2025-03-18

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$11

2025-03-18

Reiterates

Strong Buy

Reason

Citizens Capital Markets

Reni Benjamin

Hold

Buy

Upgrades

2025-03-18

Reason

Citizens Capital Markets

Reni Benjamin

Price Target

2025-03-18

Upgrades

Hold

Buy

Reason

Citizens JMP upgraded Sana Biotechnology to Outperform from Market Perform with a $5 price target. The firm cites its cash per share and platform value analysis for the upgrade. Sana reported Q4 results and provided corporate updates, including longer follow-up from the Upsala IST demonstrating three-month islet cell viability, the analyst tells investors in a research note. Citizens says that with three-month follow-up from the modified pancreatic islet cell IST program validating the Hypoimmune platform in type 1 diabetes, SC291 data in autoimmune diseases expected in 2025, and a cash position of $152.5M, Sana shares are undervalued.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Sana Biotechnology Inc (SANA.O) is -6.12, compared to its 5-year average forward P/E of -5.17. For a more detailed relative valuation and DCF analysis to assess Sana Biotechnology Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.17

Current PE

-6.12

Overvalued PE

-1.76

Undervalued PE

-8.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.40

Current EV/EBITDA

-5.07

Overvalued EV/EBITDA

-0.44

Undervalued EV/EBITDA

-8.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.03

Current PS

4.09

Overvalued PS

0.42

Undervalued PS

-0.35